CN101239099A - Application of Chinese medicinal composition in preparing medicament for treating chronic cardiac insufficiency - Google Patents
Application of Chinese medicinal composition in preparing medicament for treating chronic cardiac insufficiency Download PDFInfo
- Publication number
- CN101239099A CN101239099A CNA200710056720XA CN200710056720A CN101239099A CN 101239099 A CN101239099 A CN 101239099A CN A200710056720X A CNA200710056720X A CN A200710056720XA CN 200710056720 A CN200710056720 A CN 200710056720A CN 101239099 A CN101239099 A CN 101239099A
- Authority
- CN
- China
- Prior art keywords
- radix
- cardiac insufficiency
- chinese medicine
- chronic cardiac
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000001684 chronic effect Effects 0.000 title claims abstract description 20
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 26
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000009636 Huang Qi Substances 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000037149 energy metabolism Effects 0.000 claims description 5
- 230000002861 ventricular Effects 0.000 claims description 5
- 238000004904 shortening Methods 0.000 claims description 4
- 230000008828 contractile function Effects 0.000 claims description 2
- 210000005240 left ventricle Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 2
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 244000131316 Panax pseudoginseng Species 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 description 16
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 16
- 235000008434 ginseng Nutrition 0.000 description 16
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 16
- 235000021286 stilbenes Nutrition 0.000 description 16
- 239000006187 pill Substances 0.000 description 11
- -1 reflux Substances 0.000 description 11
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 241000304195 Salvia miltiorrhiza Species 0.000 description 5
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000008412 qishen yiqi Substances 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000009798 Shen-Fu Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention is related to the use of a Chinese medicine composition serving for preparing drug for curing chronic cardiac insufficiency. The composition is formed of the following raw materials by weight: 22.2% to 66.8% of astragalus, 11.6% to 33.4% of salvia, 2.5% to 13.5% of panax notoginseng, 14.5% to 44.3% of lignum dalbergiae odoriferae.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the application of QISHEN YIQI DIWAN in the medicine of preparation prevention and treatment chronic cardiac insufficiency.
Background technology
Cardiac insufficiency claims congestive heart failure (being called for short heart failure or heart failure) again, be meant under the normal situation of venous return, because the overweight left cardiac output that causes of former heart damage or the long-term pressure of ventricle or volume load reduces and ventricular filling pressure raises, clinically with tissue blood hypoperfusion and pulmonary circulation and (or) body circulation blood stasis is a kind of clinical syndrome of principal character, show as cardiopalmus severe palpitation, shortness of breath and fatigue, dyspnea, limds edema, liver and swell and ache etc.Chronic cardiac insufficiency almost is all organic heart disease patients' final home to return to, and this disease clinical onset rate height is one of difficult medical problem of primary study.
The treatment of cardiac insufficiency, doctor trained in Western medicine medicine commonly used comprises diuretic, vasodilation, cardiac tonic, Folium Digitalis Purpureae, non-sample Radix Rehmanniae class positive inotropic medicament, converting enzyme inhibitor, beta receptor inhibitor etc., but side effect is in various degree all arranged or use taboo; Chinese patent medicine commonly used is mainly SHENFU ZHUSHEYE, SHENMAI ZHUSHEYE etc., but curative effect is not satisfactory, and untoward reaction in various degree occurs.
QISHEN YIQI DIWAN is made up of the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng and Lignum Dalbergiae Odoriferae, is produced by Tianjin Tasly Pharmaceutical Co., Ltd, and is evident in efficacy in order to the angina pectoris of treatment coronary heart disease with qi deficiency and blood stasis, do not have any obvious toxic and side effects.Chinese patent application CN1375316A discloses the composition of said preparation, method for making and the purposes aspect angina pectoris, Chinese patent application CN200510013503.3A, CN200510013504.8, CN200510013505.2, CN200510013506.7, CN200510013507.1 discloses said composition respectively at preparation control medicine for senile dementia, preparation suppresses the albumin outside leakage medicine, preparation suppresses the application in the mast cell degranulation medicine, preparation prevents and treats the application in the high altitude anoxia medicine, application in the preparation treatment acute pancreatitis medicine, but this medicine does not appear in the newspapers as yet in the effect aspect the control chronic cardiac insufficiency.
Summary of the invention
The purpose of this invention is to provide the purposes of a kind of Chinese medicine composition in the medicine of preparation treatment chronic cardiac insufficiency, said composition is prepared from by the following raw materials by weight percent medicine: the Radix Astragali 22.2%～66.8%, Radix Salviae Miltiorrhizae 11.6%～33.4%, Radix Notoginseng 2.5%～13.5%, Lignum Dalbergiae Odoriferae 14.5%～44.3%.
Chinese medicine composition of the present invention, person's left ventricle contractile function that can improve the chronic cardiac insufficiency, increase chronic cardiac insufficiency person's left ventricular ejection mark (LVEF) and shortening fraction (FS), the person's that improves the chronic cardiac insufficiency energy metabolism, showing as ATP raises, ATP/ADP ratio raises, and can close (energy charge, EC) rising.
Chinese medicine composition of the present invention, its preferred proportioning is the Radix Astragali 30.8%～57.2%, Radix Salviae Miltiorrhizae 15.4%～28.6%, Radix Notoginseng 3.5%～6.5%, Lignum Dalbergiae Odoriferae 20.6%～38.2%; Its best proportioning is the Radix Astragali 44.7%, Radix Salviae Miltiorrhizae 26.7%, Radix Notoginseng 6.3%, Lignum Dalbergiae Odoriferae 22.3%; Perhaps be the Radix Astragali 41.2%, Radix Salviae Miltiorrhizae 23.8%, Radix Notoginseng 4.5%, Lignum Dalbergiae Odoriferae 30.5%.
Chinese medicine composition of the present invention, can extract preparation to crude drug according to the method for routine or the method for prior art respectively, mix then, preferably, prepare: Radix Salviae Miltiorrhizae, the pseudo-ginseng of learning from else's experience and pulverizing according to following method, decocting boils, filter, filtrate suitably concentrates the back precipitate with ethanol, and supernatant reclaims ethanol, be condensed into extractum, i.e. Salvia miltiorrhiza and Panax notoginseng extractum; The Milkvetch Root that other learns from else's experience and pulverizes, decocting boils, and filters, and filtrate suitably concentrates the back precipitate with ethanol, precipitate with ethanol again after supernatant suitably concentrates, supernatant reclaims ethanol, is condensed into extractum, i.e. Radix Astragali extractum; Get the Lignum Dalbergiae Odoriferae medical material again, add water, reflux, extract, is collected volatile oil.With above two kinds of extractum and volatile oil and adjuvant mixed evenly after, make said dosage form on any pharmaceutics of preparation, wherein preferred dosage form is a drop pill.For example, the drop pill method for making: get the Polyethylene Glycol-6000 of 2～5 times of above-mentioned Salvia miltiorrhiza and Panax notoginseng extractum, Radix Astragali extractum and extractum gross weights, water-bath is dissolved, change even after, add volatile oil of Lignum Dalbergiae Odoriferae, mixing, the method for making drop pill routinely is prepared, promptly; More solito sheet agent method can be made into tablet; Or the like.
For a better understanding of the present invention, below by the influence of Chinese medicine composition of the present invention (to call " QISHEN YIQI DIWAN extractum " in the following text) to the chronic cardiac insufficiency rat, parallel excusing from death kinetocardiography is measured left ventricular ejection mark (EF) and shortening fraction (FS), ATP, ADP, AMP are measured in cardiac muscular tissue's homogenate, and the effect of QISHEN YIQI DIWAN in the treatment chronic cardiac insufficiency is described.
Test objective:
Observe the therapeutical effect of QISHEN YIQI DIWAN for the chronic cardiac insufficiency rat.
Material and method
1, animal: the SD rat, male, cleaning level, available from Shanghai Slac Experimental Animal Co., Ltd., the quality certification number: 0016807,0017299
2, be subjected to the reagent thing:
(1) QISHEN YIQI DIWAN extractum: according to the method preparation of embodiment 1, per 1 gram extractum contains the 14.3g crude drug, mouse experiment LD
50Be 25.807g/kg, convert and be rat LD
50For: 18.0649g/kg, the clinical using dosage of people is: 6.25mg/kg, Radix Astragali extractum: Salvia miltiorrhiza and Panax notoginseng extractum: volatile oil of Lignum Dalbergiae Odoriferae=1: 1: 0.0735.Deionized water dissolving.
(2) vasorel (energy metabolism regulator, VASOREL, Trimetazidine dihydrochloride): by French Les Laboratoires servier provide (SERVIER, France), every 20mg, batch number (Batch): 5J4515.Deionized water dissolving.
(3) acertil (renin angiotensin converting enzyme inhibitor, ACERTIL, Perindopril tablets): by provide by French Les Laboratoires servier (SERVIER, France), every 4mg, batch number (Batch): 5K0401.Deionized water dissolving.
Raised by the equal stomach of reagent thing route of administration, every Mus 1ml every day.
3, reagent and solution
(1) isoproterenol (Sigma, DL-Isoproterenol hydrochloride): No:15627-25G, the 055k1021 physiological saline solution, subcutaneous injection is used.
(2) heparin sodium injection (Chinese changzhou thousand red-face roleization pharmaceutical Co. Ltds): batch number: 051229,2ml:12500 unit is with normal saline dilution, 500 units/ml.
(3) chloral hydrate solution (Jiangsu TCM Hospital, the medicine system word H04001110 of Soviet Union): batch number: 060412, it is 7.5% stand-by diluting with normal saline.
4, experimental apparatus and equipment:
(1) the little processing pH meter of conventional equipment: Ph213 (HANNA), WS-1 magnetic stirring apparatus, rat oral gavage pin, shears, tweezers, vascular clamp, gauze etc.
(2) echocardiograph: the VIVID7 of GE company type
5, experiment modeling: except that rats in normal control group, model group and treatment group rat begin to carry out modeling in normal raising after 3-7 days, method is as follows: the 1st day different third kidney of subcutaneous injection (ISO) 20mg/Kg, the 2nd day different third kidney of subcutaneous injection (ISO) 10mg/Kg, the 3rd day ISO 5mg/Kg, 4-12 days ISO 3mg/Kg.
6, the experiment grouping:
142 of SD rats, body weight 201.86 ± 6.68g is divided into two groups at random: normal group (n=18) and model group (n=124).Test the model group rat that began in first day and give the modeling of ISO subcutaneous injection, method is the same, after one month, rat is ultrasonic in the test section, the model group rat that will partly survive at random is divided into stilbene ginseng QI invigorating high dose group (n=16), dosage group (n=16) in the stilbene ginseng QI invigorating, stilbene ginseng QI invigorating low dose group (n=16), vasorel group (n=15) and acertil group (n=15) residue model group (n=16), stilbene ginseng QI invigorating height, in, the every respectively Mus of low dose group rat is irritated stomach stilbene ginseng QI invigorating extractum 78.125mg/kg every day, 39.063mg/kg and 19.531mg/kg, the every Mus of vasorel group rat is irritated stomach vasorel 10mg/kg every day, and the every Mus of acertil group rat is irritated stomach 0.417mg/kg every day.Treatment continued for 4 weeks, once a day, put to death 6-10 rat for every group after 4 weeks of treatment, surplus SD rat continued treatment, and the 6th week put to death.
7, observation index:
(1) rat ordinary circumstance: mobility, body weight, death toll etc.
(2) the ultrasonic index of rat: rat chloral hydrate anesthesia before experiment finishes, row two-dimensional ultrasound record left ventricular ejection mark (EF) and shortening fraction (FS).
(3) cardiac muscular tissue's homogenate: measure ATP, ADP, AMP.Sample disposal:
A.ATP measures
A) reagent is prepared
Triethanolamine buffer (50mmol/L): pH7.2; NADP 10mmol/l; MgCl
20.1mol/l; Glucose 0.5mol/l;
Enzyme buffer liquid: G6P-DH (80U/ml): HK (100U/ml)=1: 1
ATP standard substance 100 μ mol/l; 200 μ mol/l; 400 μ mol/l.
Blank buffer TEA: NADP: MgCl
2: glucose=7: 1: 1: 1
Reaction buffer is the 1mmol/lATP that every milliliter of blank buffer adds 20 μ l
B) experimental procedure
Blank tube reaction pipe
Sample 200 μ l
Neutral perchloric acid 200 μ l
Blank buffer 1000 μ l
Reaction buffer 1000 μ l
Enzyme buffer liquid 20 μ l 20 μ l
Enzyme-added mixing is also put back in the ice bath, and it is abundant to put into 37 degree water after all adding together, and in wavelength 339nm place colorimetric, with the air zeroing, the blank pipe of note is A behind the 20min
0, reaction tube is A.ΔA＝A-A
0
Δ A is directly proportional with the concentration of ATP.
B.ADP/AMP
A) reagent is prepared
Triethanolamine buffer (50mmol/L): PH8.0; PEP/MgSO
4/ KCl (PEP 14mmol/l, MgSO
40.5mol/l, KCl1.8mol/l); NADH (16mmol/l); LDH 2500U/ml; PK 2000U/ml; MK 100U/ml.
Reaction buffer TEA (600 μ l)+PEP/MgSO
4/ KCl (120 μ l)+NADH (35 μ l)+LDH (20 μ l)
Standard substance configuration: AMP 200 μ mol/l 300 μ mol/l 400 μ mol/l
The ATP that should contain same concentrations in the AMP standard substance
ADP?100μmol/l 150μmol/l 200μmol/l
B) experimental procedure
Blank tube reaction pipe
Sample 600 μ l
Neutral perchloric acid 600 μ l
Reaction buffer 600 μ l 600 μ l
The reading note A1 of mixing 5min 339nm place
PK 20μl 20μl
The reading note A2 of mixing 20min 339nm place
MK 100μl 100μl
The reading note A3 of mixing 20min 339nm place
Δ A
ADP=Δ A
Sample (A2-A1)-Δ A
Blank (A2-A1)Δ A
ADPBe directly proportional with ADP concentration in the sample
A
AMP=Δ A
Sample (A3-A2)-Δ A
Blank (A3-A2)Δ A
AMPBe directly proportional with AMP concentration in the sample
7, data analysis and statistics
Represent measurement data with mean ± standard deviation, measurement data relatively adopts ANOVA to analyze for many groups, relatively adopts the S-N-K check between group in twos; Two groups of means relatively adopt the T check; Enumeration data adopts X 2 test.All statistics utilize the SPSS12.0 software analysis to finish, and P＜0.05 is for there being significant difference.
The result
(1) ordinary circumstance, body weight and mortality rate are relatively: death toll and body weight are compared with normal group and are seen Table 1 after the different third kidney modeling, and rats death digital display work is higher than normal group behind the different third kidney modeling type, and significant difference is arranged, modeling after the 28th day body weight alleviate than normal group.Drug therapy is carried out in modeling after 30 days, each treatment group death toll and weight ratio see Table 2.1 model group rats death only during the treatment, body weight does not have significant change between each group.
Normal group, model group mortality rate, body weight comparative result (body weight unit: g) before table 1 treatment
Through check, normal group and model group rats death are counted P=0.044 (Pearson Chi-square=4.620); * compare P＜0.05 with normal group
Respectively organize (body weight unit: g) of death toll, weight ratio after table 2 treatment
(2) rat ultrasoundcardiogram comparative result: 30 days model group and normal group are respectively got 8 rats underwent echocardiography after the different third kidney modeling, the results are shown in Table 3, and model group EF and FS are starkly lower than normal group, and significant difference is arranged.Drug therapy is carried out in modeling after 30 days.
(testing 30 days) normal group and model group ultrasoundcardiogram are relatively before table 3 treatment
* compare P＜0.05 with normal group;
After 4 weeks of treatment and 6 weeks, get 46 capable echocardiography of every group of rat respectively, each is organized ultrasoundcardiogram and relatively sees Table 4.Results suggest: model group and each medication therapy groups EF, FS all are lower than normal group, and each medication therapy groups FS all is higher than model group.Stilbene ginseng QI invigorating high dose group, vasorel group EF are higher than model group, and significant difference is arranged.Stilbene ginseng QI invigorating high dose group EF is higher than the acertil group significant difference.
Table 4 is respectively organized the rat ultrasoundcardiogram relatively after 6 weeks of treatment:
* compare P＜0.05 with normal group; # compares with model group, P＜0.05; $ compares P＜0.05 with stilbene ginseng high dose group; ﹠amp; Compare P＜0.05 with dosage group in the stilbene ginseng; % compares P＜0.05 with stilbene ginseng low dosage; @ compares with the vasorel group, P＜0.05
(4) rat heart muscle high-energy phosphate compound content relatively
Treat and respectively organize rat heart muscle high-energy phosphate compound content 6 weeks and see Table 5.
Table 5 treatment 6 all rat heart muscle high-energy phosphate compound content
* compare P＜0.05 with normal group; # compares with model group, P＜0.05; $ compares P＜0.05 with stilbene ginseng high dose group; ﹠amp; Compare P＜0,05 with dosage group in the stilbene ginseng; % compares P＜0.05 with stilbene ginseng low dosage; @ compares with the vasorel group, P＜0.05 result:
1. isoproterenol continues subcutaneous injection and can cause rat pathology to present between heart matter to be fibrosis, calcification, connective tissue proliferation, normal myocardium cell and to be island, the cardiac muscle fiber arrangement disorder, part is with inflammatory cell infiltration, ultrasonic cardiography diagram LVd, LVs, EDV, ESV obviously increase, EF, FS, IVS, LVPW obviously reduce, and similar chronic cardiac insufficiency changes.
2. in stilbene ginseng QI invigorating extractum treatment SD heart failure 6 weeks of rat, can improve heart failure rat cardiac function LVEF and FS.
3. the treatment of stilbene ginseng QI invigorating extractum can improve the energy metabolism of chronic heart failure rat, and results change and clinical Western medicine vasorel commonly used, acertil are similar.
To sum up, stilbene ginseng QI invigorating extractum can increase heart failure rat cardiac function LVEF and FS as can be seen, improves the left chamber contractility of chronic cardiac insufficiency rat, improves the energy metabolism of chronic heart failure rat.
The specific embodiment
Below in conjunction with embodiment medicine of the present invention is described further, following each embodiment only is used to the present invention is described and is not limitation of the present invention.
Embodiment one
Get Radix Astragali 86.5g, Radix Salviae Miltiorrhizae 21.3g, Radix Notoginseng 3.5g, Lignum Dalbergiae Odoriferae 20.6g, adjuvant Polyethylene Glycol-600030g.Will be through Radix Salviae Miltiorrhizae, the Radix Notoginseng of pulverizing, decocting boils 2 times, adds 7 times of water gagings at every turn, each 2 hours, merge decoction liquor, filter, filtrate is concentrated into 900ml, add 95% ethanol, make determining alcohol reach 70%, left standstill 12～24 hours, filter, reclaim ethanol, being condensed into relative density is the extractum of 1.32～1.38 (50～60 ℃); To decoct with water 2 times through the Radix Astragali of pulverizing, add 6 times of water gagings at every turn, extracted successively 2 hours, 1 hour, merging filtrate is when being concentrated into the 1500ml left and right sides, adding 95% ethanol, to make determining alcohol be 60%, left standstill 12～24 hours, filters, filtrate recycling ethanol, when being concentrated into the 400ml left and right sides, adding 95% ethanol, to make determining alcohol be 80%, left standstill 12～24 hours, filter, filtrate recycling ethanol, being condensed into relative density is the extractum of 1.32～1.38 (50～60 ℃); Get Lignum Dalbergiae Odoriferae, add 5 times of water gagings, reflux, extract, 5 hours is collected volatile oil; Get above-mentioned Salvia miltiorrhiza and Panax notoginseng extractum, Radix Astragali extractum, add volatile oil of Lignum Dalbergiae Odoriferae, mixing.
Embodiment two
Get Salvia miltiorrhiza and Panax notoginseng extractum, Radix Astragali extractum and the Polyethylene Glycol-6000 of embodiment one, water-bath is dissolved, and after change is even, adds volatile oil of Lignum Dalbergiae Odoriferae, and mixing moves in the drop pill machine, makes 1000 drop pill.
Embodiment three
Get Radix Astragali 40.6g, Radix Salviae Miltiorrhizae 44.8g, Radix Notoginseng 11.2g, Lignum Dalbergiae Odoriferae 38.6g, adjuvant Polyethylene Glycol-600030g makes 1000 drop pill by the method for embodiment one and embodiment two.
Embodiment four
Get Radix Astragali 77.3g, Radix Salviae Miltiorrhizae 22.8g, Radix Notoginseng 4.8g, Lignum Dalbergiae Odoriferae 30.5g, adjuvant Polyethylene Glycol-600028g, make 1000 drop pill by the method for embodiment one and embodiment two.
Embodiment five
Get Radix Astragali 42.3g, Radix Salviae Miltiorrhizae 39.2g, Radix Notoginseng 8.2g, Lignum Dalbergiae Odoriferae 46.8g, adjuvant Polyethylene Glycol-600025g, make 1000 drop pill by the method for embodiment one and embodiment two.
Embodiment six
Get Radix Astragali 65.2g, Radix Salviae Miltiorrhizae 38.9g, Radix Notoginseng 9.3g, Lignum Dalbergiae Odoriferae 32.5g, adjuvant Polyethylene Glycol-600040g, make 1000 drop pill by the method for embodiment one and embodiment two.
Embodiment seven
Get Radix Astragali 56.2g, Radix Salviae Miltiorrhizae 32.5g, Radix Notoginseng 6.2g, Lignum Dalbergiae Odoriferae 41.6g, adjuvant Polyethylene Glycol-600022g, make 1000 drop pill by the method for embodiment one and embodiment two.
Embodiment eight
Get Radix Astragali 36.5g, Radix Salviae Miltiorrhizae 32.4g, Radix Notoginseng 6.2g, Lignum Dalbergiae Odoriferae 41.7g, adjuvant Polyethylene Glycol-600022g, make 1000 drop pill by the method for embodiment one and embodiment two.
Embodiment nine
Get Radix Astragali 65.6g, Radix Salviae Miltiorrhizae 25.8g, Radix Notoginseng 9.5g, Lignum Dalbergiae Odoriferae 46.4g, make extractum by the preparation technology of embodiment one, qinghuo reagent, sucrose and dextrin are made 200 in tablet by weight 1: 3: 1 ratio according to conventional method.
Embodiment ten
Get Radix Astragali 35.5g, Radix Salviae Miltiorrhizae 50.8g, Radix Notoginseng 16.3g, Lignum Dalbergiae Odoriferae 52.3g, make extractum by the preparation technology of embodiment one, qinghuo reagent, sucrose and dextrin are made 125 bags of granules in 1: 3: 1 ratio according to conventional method.
Embodiment 11
Get Radix Astragali 86.5g, Radix Salviae Miltiorrhizae 21.3g, Radix Notoginseng 3.5g, Lignum Dalbergiae Odoriferae 20.6g, make extractum by the preparation technology of embodiment one, qinghuo reagent, sucrose and dextrin are made granule in 1: 3: 1 ratio according to conventional method, record capsule according to conventional method.
Claims (8)
1. the Chinese medicine composition purposes in the medicine of preparation treatment chronic cardiac insufficiency, said composition is prepared from by the following raw materials by weight percent medicine: the Radix Astragali 22.2%～66.8%, Radix Salviae Miltiorrhizae 11.6%～33.4%, Radix Notoginseng 2.5%～13.5%, Lignum Dalbergiae Odoriferae 14.5%～44.3%.
2. purposes as claimed in claim 1 is characterized in that described Chinese medicine composition person's left ventricle contractile function that can improve the chronic cardiac insufficiency.
3. purposes as claimed in claim 2 is characterized in that the described Chinese medicine composition person's that can increase the chronic cardiac insufficiency left ventricular ejection mark.
4. purposes as claimed in claim 2 is characterized in that the described Chinese medicine composition person's that can increase the chronic cardiac insufficiency shortening fraction.
5. purposes as claimed in claim 1 is characterized in that the described Chinese medicine composition person's that can improve the chronic cardiac insufficiency energy metabolism.
6. as arbitrary purposes of claim 1～5, wherein said Chinese medicine composition is prepared from by the following raw materials by weight percent medicine: the Radix Astragali 30.8%～57.2%, Radix Salviae Miltiorrhizae 15.4%～28.6%, Radix Notoginseng 3.5%～6.5%, Lignum Dalbergiae Odoriferae 20.6%～38.2%.
7. purposes as claimed in claim 6, wherein said Chinese medicine composition is prepared from by the following raw materials by weight percent medicine: the Radix Astragali 44.7%, Radix Salviae Miltiorrhizae 26.7%, Radix Notoginseng 6.3%, Lignum Dalbergiae Odoriferae 22.3%.
8. purposes as claimed in claim 6, wherein said Chinese medicine composition is prepared from by the following raw materials by weight percent medicine: the Radix Astragali 41.2%, Radix Salviae Miltiorrhizae 23.8%, Radix Notoginseng 4.5%, Lignum Dalbergiae Odoriferae 30.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710056720XA CN101239099A (en) | 2007-02-06 | 2007-02-06 | Application of Chinese medicinal composition in preparing medicament for treating chronic cardiac insufficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710056720XA CN101239099A (en) | 2007-02-06 | 2007-02-06 | Application of Chinese medicinal composition in preparing medicament for treating chronic cardiac insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101239099A true CN101239099A (en) | 2008-08-13 |
Family
ID=39931109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200710056720XA Pending CN101239099A (en) | 2007-02-06 | 2007-02-06 | Application of Chinese medicinal composition in preparing medicament for treating chronic cardiac insufficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101239099A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293822A (en) * | 2010-06-28 | 2011-12-28 | 天津天士力制药股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicines used for reducing occurrence of cardiovascular events after acute myocardial infarction |
| CN101675946B (en) * | 2008-09-19 | 2012-04-18 | 天津天士力制药股份有限公司 | Application of a traditional Chinese medicine in preparing a medicine for reducing inflammatory reaction after PCI |
| CN110339202A (en) * | 2018-04-04 | 2019-10-18 | 天士力医药集团股份有限公司 | A kind of pharmaceutical composition and its application |
-
2007
- 2007-02-06 CN CNA200710056720XA patent/CN101239099A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101675946B (en) * | 2008-09-19 | 2012-04-18 | 天津天士力制药股份有限公司 | Application of a traditional Chinese medicine in preparing a medicine for reducing inflammatory reaction after PCI |
| CN102293822A (en) * | 2010-06-28 | 2011-12-28 | 天津天士力制药股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicines used for reducing occurrence of cardiovascular events after acute myocardial infarction |
| US9211310B2 (en) | 2010-06-28 | 2015-12-15 | Tasly Pharmaceutical Group Co., Ltd | Use of a Chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction |
| CN110339202A (en) * | 2018-04-04 | 2019-10-18 | 天士力医药集团股份有限公司 | A kind of pharmaceutical composition and its application |
| US11491173B2 (en) | 2018-04-04 | 2022-11-08 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040109904A1 (en) | Antineoplastic drug | |
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN101007151A (en) | Traditional Chinese medicine and its preparation for treating chronic nephritis | |
| CN101584807A (en) | Application of traditional Chinese medicine composition in preparing medicament of insulin sensitizer | |
| CN102631526B (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN101239099A (en) | Application of Chinese medicinal composition in preparing medicament for treating chronic cardiac insufficiency | |
| CN106176773A (en) | Berberine hydrochloride and stachyose composition compositions and application | |
| CN102429977B (en) | Medicine for treating diabetes | |
| CN100502843C (en) | Chinese medicine for treating mammary gland cystoma, mammitis and preparation method of its film coated tablet | |
| CN102366433B (en) | Application of Chinese medicinal chrysanthemum extract in preparing medicaments with lipase activity-inhibiting action | |
| CN101347543A (en) | Chinese medicine compound and preparation method thereof | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN101810826A (en) | Chinese medicament for treating liver cancer | |
| CN101468087A (en) | Method for preparing 'Xinmaitong' granular formulation | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN102872385A (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN1943661A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN101288763A (en) | Medicine for treating liver cancer and preparing process thereof | |
| Tian-zhan et al. | Synergistic effects of Yiqi Huazhuo Gushen herbal formula and valsartan on metabolic syndrome complicated with microalbuminuria | |
| CN107693593B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease | |
| CN102370694B (en) | Application of Chinese herbal medicine shrubby sophora extract in preparation of weight losing and lipid lowering medicament or medicament with lipase activity suppression effect | |
| CN102397304B (en) | Application of Chinese herbal medicine ginkgo biloba extract in preparation of medicament for reducing weight and lipid or preparation of medicament with lipase activity inhibitory action | |
| CN102357106B (en) | Application of Chinese herbal medicine campsis grandiflora extracts in preparation of weight-losing lipid-lowering medicines or medicines with lipase activity inhibition effect | |
| CN104436049A (en) | Traditional Chinese medicine composition for treating heart disease | |
| CN102068605B (en) | Traditional Chinese medicine composition for treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20080813 |